Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia

Martin F.M. de Rooij, Annemieke Kuil, Willem Kraan, Marie Jose' Kersten, Steven P. Treon, Steven T. Pals, and Marcel Spaargaren

Disclosures: Marcel Spaargaren has previously received research support from Pharmacyclics Inc. and Johnson & Johnson. Marie Jose Kersten has previously received honoraria from Janssen Pharmaceuticals. Steven P. Treon has previously received active research funding, consulting fees, and/or speaking honoraria from Janssen Pharmaceuticals Inc., Pharmacyclics Inc., and Gilead Pharmaceuticals. The remaining authors declare no competing financial interest.

Contributions: MFMdR designed the research, performed experiments, analyzed the data, designed the figures and wrote the manuscript; AK and WK performed experiments; MJK and SPT provided material and reviewed the manuscript; STP co-supervised the study and reviewed the manuscript and MS designed the research, supervised the study, analyzed the data, and wrote and revised the manuscript.